Merck & Co. Inc

FDA Regulatory Profile

Summary

Total Recalls
5
510(k) Clearances
0
Inspections
25
Compliance Actions
1

Recent Recalls

NumberClassProductDate
D-0584-2025Class IIBelsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card conJuly 21, 2025
D-1310-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30),January 13, 2014
D-1309-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/10 mg, a) 30 count blister (NDC 66582-320-30),January 13, 2014
D-1312-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30),January 13, 2014
D-1311-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister (NDC 66582-322-30),January 13, 2014